Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities

Immune checkpoint inhibitors (ICIs) are newly approved treatments for advanced malignancies that are increasing survival. The mechanism of these drugs, non-specifically activating T cells, also leads to immune-mediated damage of tissue or immune-related adverse events (IRAE). IRAEs with rheumatic ph...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:RMD Open
Hauptverfasser: Cappelli, Laura C, Shah, Ami A, Bingham, Clifton O
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2016
Schlagworte:
Autoimmunity
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5051426/
https://ncbi.nlm.nih.gov/pubmed/27752360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000321
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge